Variant · Indel
NF1 D1976fs
CI-VAR-00000446Explore in graph →CIViC 4665
Curated evidence
Evidence by cancer (1 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 36670111
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Malignant Pancreatic Neoplasm1 | ||||||||
| KRAS G12D AND GNAS R201C AND NF1 D1976fs | Trametinib | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11714In this clinical trial, 18 patients with pancreatic cancer were recruited. In this case, the patient (82 y/F) with pancreatic cancer harboring GNAS R201C, KRAS G12D and, NF1 D1976fs, was treated with … (full text at CIViC) PMID 36670111 · Shaya et al., 2023 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available